Global Infliximab Market, By Type (Inflectra, Renflexis, Others), Route of Administration (Subcutaneous, Intravenous, Parenteral), Molecule Type (Monoclonal Antibodies, Peptide, Protein, Small Molecule), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights Global Infliximab Market
The infliximab market is expected to witness market growth at a rate of 11.50% in the forecast period of 2022 to 2029. Data Bridge Market Research report on infliximab market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in healthcare sector globally is escalating the growth of infliximab market.
Infliximab, refers to a chimeric monoclonal antibody that is used as medication for treating various autoimmune diseases. It has been proven effective in diseases such as ulcerative colitis, ankylosing spondylitis, Behçet's disease, Crohn's disease, rheumatoid arthritis, psoriasis and psoriatic arthritis.
The rise in the geriatric population across the globe acts as one of the major factors driving the growth of infliximab market. The rise in Research and Development in pharmaceutical companies for enhancing the product and increase in demand for biosimilar drugs due to their cost-effectiveness accelerate the market growth. The development in commercial pipelines and rise in the incidence of chronic diseases including ankylosing spondylitis, Crohn's disease, rheumatoid arthritis and Behçet's disease, among others further influence the market. Additionally, development in technology, supportive government legislation, rise in investment by public and private organizations, surge in healthcare expenditure and abbreviated regulatory approval process and concept of interchangeability positively affect the infliximab market. Furthermore, research on new indications and patent expiry of blockbuster biologics extend profitable opportunities to the market players in the forecast period of 2022 to 2029.
On the other hand, complexities in manufacturing and resistance from biologics manufacturers are expected to obstruct the market growth. Excess competition among manufacturers is projected to challenge the infliximab market in the forecast period of 2022-2029.
This infliximab market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info infliximab market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Infliximab Market Scope and Market Size
The infliximab market is segmented on the basis of type, route of administration, molecule type and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the infliximab market is segmented into inflectra, renflexis and others.
- On the basis of route of administration, the infliximab market is segmented into subcutaneous, intravenous and parenteral.
- On the basis of molecule type, the infliximab market is segmented into monoclonal antibodies, peptide, protein and small molecule.
- On the basis of distribution channel, the infliximab market is segmented into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.
Infliximab Market Country Level Analysis
The infliximab market is analyzed and market size information is provided by country, type, route of administration, molecule type and distribution channel as referenced above.
The countries covered in the global infliximab market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the infliximab market due to the presence of developed healthcare infrastructure within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the increase in the research and development activities in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The infliximab market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Infliximab Market Share Analysis
The infliximab market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related infliximab market.
Some of the major players operating in the infliximab market are Amgen Inc., Pfizer Inc., Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd, Allergan, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Endo International plc, Sun Pharmaceutical Industries Ltd, Mylan N.V., Apotex Inc., and Biocad, and others.